Moderna reported third quarter 2025 revenue of $1 billion, a 45% year-over-year decline, resulting in a net loss of $200 million ($0.51 loss per share). Despite the revenue drop driven by lower COVID vaccine demand, the company demonstrated aggressive financial discipline, reducing combined costs of sales, R&D, and SG&A by 34% compared to the prior year. The company lowered its 2025 cash cost guidance by $900 million to $4.6 billion and raised its year-end cash outlook to $6.5–$7.0 billion. Pipeline updates were mixed: the CMV vaccine (mRNA-1647) failed its Phase III primary endpoint and was discontinued for congenital CMV, while the flu vaccine (mRNA-1010) showed positive Phase III data and the oncology program (mRNA-4359) reported encouraging Phase Ib data. Management reaffirmed a target for cash breakeven by 2028.
| Metric | Value | Change |
|---|---|---|
| Total Revenue | $1.0 billion | -45% YoY |
| Net Loss | $200 million | Income of $13M in Q3 2024 |
| Loss Per Share | $0.51 | EPS of $0.03 in Q3 2024 |
| Cash and Investments | $6.6 billion | Down from $7.5B in Q2 |
| R&D Expenses | $801 million | -30% YoY |
| Cost of Sales | $207 million | -60% YoY |
Aggressive Financial Restructuring: Moderna is executing a massive cost-cutting program, reducing GAAP operating expenses by over $1 billion versus initial 2025 guidance. This indicates a strategic pivot from pandemic growth to efficiency, extending their cash runway to support the 2028 breakeven goal. Management stated they are reducing projected 2025 cash costs by approximately $900 million since the beginning of the year.
Commercial Portfolio Diversification: The company is leveraging its COVID infrastructure to launch mNEXSPIKE (new COVID vaccine) and mRESVIA (RSV). mNEXSPIKE now comprises 55% of their COVID volume, and strategic manufacturing partnerships in Canada, UK, and Australia are beginning to contribute revenue, reducing reliance on the US market.
Pipeline Prioritization and Risk Management: Following the CMV failure, management is strictly prioritizing R&D spend. They are pausing large Phase III infectious disease trials (like EBV) until post-2028, focusing current resources on Oncology (INT) and late-stage respiratory vaccines (Flu/COVID combo) that have nearer-term commercial potential or partner funding.
Oncology as a Growth Driver: The company is doubling down on Oncology, specifically the INT program (partnered with Merck) and mRNA-4359. With multiple Phase III and Phase II trials enrolling, Moderna is signaling that Oncology, rather than infectious disease vaccines, will be a primary revenue driver post-2028.
Major Pipeline Setback (CMV): The discontinuation of the CMV vaccine (mRNA-1647) for congenital CMV removes a significant high-value potential product from the near-term pipeline. Management admitted that the scientific hypothesis regarding pentamer neutralizing antibodies was incorrect, raising questions about their platform's efficacy against latent viruses.
Steady Revenue Decline: Total revenue fell 45% year-over-year to $1 billion, driven by a 30% drop in U.S. COVID vaccinations. The company is guiding for a continued decline of 15-33% for the full year, highlighting the difficulty of replacing the massive pandemic revenue stream.
Extended Path to Profitability: Despite cutting costs by nearly 50% from 2023 levels, the company still posted a $200M net loss and maintains a 2028 breakeven target. This long timeline relies on the successful launch and market uptake of products (Flu, Oncology) that are still in clinical trials or regulatory review.
Clinical Trial Delays: The Norovirus program failed to accrue sufficient cases for an interim analysis, requiring a second season of enrollment. This delays potential data readouts and revenue realization, adding execution risk to the non-COVID pipeline.
Overall: Management exhibited a tone of disciplined resilience, acknowledging the significant setback of the CMV trial failure while emphasizing their aggressive success in cost restructuring. Stéphane Bancel and Jamey Mock were particularly firm on financial targets, while Stephen Hoge maintained a scientific, data-driven demeanor when explaining clinical setbacks.
Confidence: MEDIUM - Management is highly confident in their ability to cut costs and manage cash flow, but confidence in revenue growth is tempered by the declining COVID market and the recent failure of a key pipeline asset (CMV).
$1.6 billion to $2.0 billion
$6.5 billion to $7.0 billion
~$5.3 billion (midpoint)
$4.6 billion
2028
Hedging & Uncertainty: Management used frequent hedging language regarding future revenue drivers and clinical outcomes, particularly around the 2028 breakeven target. Phrases like 'we believe will advance,' 'expect to refile,' and 'hopeful that with this additional second season' indicate uncertainty in clinical timelines and regulatory approvals. However, hedging was absent regarding cost control, where language was definitive: 'we are now on track to beat our 2025 cost plan.' This contrast suggests high confidence in internal operational control but lower confidence in external market and regulatory factors.
We remain highly focused on financial discipline. - Stéphane Bancel, CEO
We are discontinuing development in congenital CMV. - Stephen Hoge, President
We are now on track to beat our 2025 cost plan by over $1 billion on a GAAP basis... - James Mock, CFO
Prevention of infection with the herpes virus or in CMV was an incredibly high bar. - Stephen Hoge, President
We continue to target cash breakeven in 2028. - James Mock, CFO
Analyst Sentiment: Analysts were skeptical about the feasibility of the 2028 breakeven target given the CMV failure and declining COVID revenue, pressing for details on what specific products would drive growth.
Management Responses: Management deflected specific revenue growth questions to the upcoming Analyst Day but remained firm on their cost-cutting ability and the strategic logic of prioritizing specific pipeline assets.
CMV Failure and Scientific Implications
Cost Reduction Specifics and Program Prioritization
2028 Breakeven Strategy and Revenue Drivers
mNEXSPIKE Launch and Market Share
Moderna is successfully executing a painful but necessary restructuring to survive the post-pandemic cliff. The 34% reduction in operating costs and the $900 million improvement in cash guidance demonstrate strong financial discipline. However, the investment thesis is currently impaired by the failure of the CMV program—a key future growth engine—and the continued steep decline in COVID revenues. While the flu and oncology pipelines offer hope, the 2028 breakeven target remains a distant goal dependent on successful execution in highly competitive markets. The stock is likely to remain range-bound until clinical data from flu or oncology programs validates the non-COVID growth story.
COVID vaccination rates in the U.S. are down 30% year-over-year, indicating a permanent shift in consumer behavior and market demand away from pandemic-era prophylaxis.
Moderna is successfully navigating global regulatory agencies, securing approvals for mNEXSPIKE and mRESVIA in 40 countries and establishing strategic manufacturing partnerships in Canada, UK, and Australia.